Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | MC4R | P32245 | 1/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15709181 | 0.98 | SIGMAR1 (0.55) | SIGMAR1LMNAPOLBMC4RDRD4 | |
| SCHEMBL19049578 | 0.90 | SIGMAR1 (0.44) | SIGMAR1LMNAALDH1A1POLBMC4R | |
| SCHEMBL9677809 | 0.83 | MAPT (0.44) | SIGMAR1 | |
| SCHEMBL24027125 | 0.83 | MC4R (0.51) | SIGMAR1LMNACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL19002393 | 0.83 | SIGMAR1 (0.48) | SIGMAR1MC4R | |
| SCHEMBL8467465 | 0.82 | DRD4 (0.49) | SIGMAR1LMNACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL18997798 | 0.80 | KMT2A (0.43) | SIGMAR1ALDH1A1 | |
| SCHEMBL21315832 | 0.79 | SIGMAR1 (0.54) | SIGMAR1LMNAALDH1A1POLB | |
| SCHEMBL122958 | 0.79 | SIGMAR1 (0.54) | SIGMAR1LMNAALDH1A1POLB | |
| SCHEMBL2435647 | 0.78 | DPP4 (0.49) | CYP1A2CYP3A4CYP2D6CYP2C19ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104768941-B | Novel benzylsulfonamide compounds useful as MoGAT-2 inhibitors | 伊莱利利公司 | 2016-08-24 | — | — | CN | disclosed |
| US-20070254872-A1 | Antibacterial Agents | GLAXO GROUP LIMITED (GB) | 2007-11-01 | — | — | US | disclosed |
| US-20070254872-A1 | Antibacterial Agents | GLAXO GROUP LIMITED (GB) | 2007-11-01 | — | — | US | disclosed |
| US-6531476-B1 | Block multiplication of virus within body and restore immune functions by virtue of inhibitory activity toward platelet activating factor | UNIVERSITE PARIS 7 - DENIS DIDEROT (FR) | 2003-03-11 | — | — | US | disclosed |
| EP-1095029-B1 | PIPERAZINE DERIVATIVES INHIBITING HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | UNIV PARIS 7 DENIS DIDEROT (FR) | 2002-09-18 | — | — | EP | disclosed |
| EP-1095029-A1 | PIPERAZINE DERIVATIVES INHIBITING HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | UNIVERSITE PARIS 7 - Denis DIDEROT (FR) | 2001-05-02 | — | — | EP | disclosed |
| WO-2000001677-A1 | PIPERAZINE DERIVATIVES INHIBITING HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | UNIVERSITE PARIS 7 - DENIS DIDEROT (FR) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254872-A1 | Antibacterial Agents | NQO2, NQO1, NDUFV2 | SIGMAR1 957/4885LMNA 2018/4885CYP1A2 1121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.